Nobilis Therapeutics is happy to announce that both of its submitted abstracts have been accepted to the Scientific Program at the 19th WPA World Congress of Psychiatry. The Congress is the official annual forum of the World Psychiatric Association that represents 140 psychiatric societies in 120 countries and supports more than 250,000 psychiatrists. It is the most recognized international gathering of key opinion leaders in psychiatry from around the globe. This year the event will take place in Lisbon, Portugal on August 21-24, 2019.

The Nobilis team will be presenting the following abstracts:

A Case Series Assessing the Use of Xenon for Treatment of PTSD and

Beneficial effects of xenon on behavior in valproic acid-induced model of autism.

Each abstract is based on the groundbreaking research conducted by the company in concert with its academic collaborators. The Nobilis team will share its learnings of Xenon’s disease-modifying effects in the treatment of patients with PTSD and its mood-stabilizing effects in an animal model of Autism Spectrum Disorder (ASD).

We look forward to seeing you at the Congress and sharing our exciting new research findings.